Review
doi: 10.1177/1352458506073522.
Epub 2007 Feb 16.
Measuring and management of anti-interferon beta antibodies in subjects with multiple sclerosis
Affiliations
- PMID: 17548434
- DOI: 10.1177/1352458506073522
Item in Clipboard
Review
Measuring and management of anti-interferon beta antibodies in subjects with multiple sclerosis
Mult Scler.
2007 Jun.
Abstract
Interferon Beta is well established as a first line agent to treat relapsing remitting Multiple Sclerosis. It frequently induces the formation of neutralising anti-Interferon Beta Antibodies (Nabs) which may abrogate the clinical efficacy of the drug. Numerous studies have shown a loss of bioactivity of the drug in the presence of Nabs. The focus has shifted to reliable quantification of Nabs and their appropriate incorporation into clinical practice. Here we review the development and persistence of Nabs, the effect on Interferon beta bioactivity, clinical and para-clinical autocome measures in trials, Nab assays and discuss management strategies to optimise the use of Interferon beta in relapsing remitting MS.
Similar articles
-
Are ex vivo neutralising antibodies against IFN-beta always detrimental to therapeutic efficacy in multiple sclerosis?Mult Scler. 2007 Jun;13(5):616-21. doi: 10.1177/1352458506072344. Epub 2007 Feb 9. Mult Scler. 2007. PMID: 17548440 Clinical Trial.
-
The clinical effect of neutralizing antibodies against interferon-beta is independent of the type of interferon-beta used for patients with relapsing-remitting multiple sclerosis.Mult Scler. 2009 May;15(5):601-5. doi: 10.1177/1352458508101946. Epub 2009 Mar 19. Mult Scler. 2009. PMID: 19299439
-
Fate of multiple sclerosis patients positive for neutralising antibodies towards interferon beta shifted to alternative treatments.Neurol Sci. 2005 Dec;26 Suppl 4:S213-4. doi: 10.1007/s10072-005-0517-3. Neurol Sci. 2005. PMID: 16388361 Clinical Trial.
-
Important sources of variability in clinical studies of neutralizing antibodies against interferon beta.J Neurol Sci. 2008 Sep 15;272(1-2):8-19. doi: 10.1016/j.jns.2008.05.004. Epub 2008 Jul 11. J Neurol Sci. 2008. PMID: 18620708 Review.
-
The clinical importance of neutralizing antibodies in relapsing-remitting multiple sclerosis.Curr Med Res Opin. 2006 Feb;22(2):223-39. doi: 10.1185/030079906X80413. Curr Med Res Opin. 2006. PMID: 16466595 Review.
Cited by
-
Antidrug Antibodies Against Biological Treatments for Multiple Sclerosis.CNS Drugs. 2022 Jun;36(6):569-589. doi: 10.1007/s40263-022-00920-6. Epub 2022 May 19. CNS Drugs. 2022. PMID: 35590041 Review.
-
Established and Emerging Immunological Complications of Biological Therapeutics in Multiple Sclerosis.Drug Saf. 2019 Aug;42(8):941-956. doi: 10.1007/s40264-019-00799-1. Drug Saf. 2019. PMID: 30830572 Review.
-
Risk Mitigation Strategies for Adverse Reactions Associated with the Disease-Modifying Drugs in Multiple Sclerosis.CNS Drugs. 2015 Sep;29(9):759-71. doi: 10.1007/s40263-015-0277-4. CNS Drugs. 2015. PMID: 26407624 Free PMC article. Review.
-
Review of the pharmacoeconomics of early treatment of multiple sclerosis using interferon beta.Neuropsychiatr Dis Treat. 2013;9:1339-49. doi: 10.2147/NDT.S33949. Epub 2013 Sep 16. Neuropsychiatr Dis Treat. 2013. PMID: 24072971 Free PMC article. Review.
-
Clinical testing for neutralizing antibodies to interferon-β in multiple sclerosis.Ther Adv Neurol Disord. 2013 Jan;6(1):3-17. doi: 10.1177/1756285612469264. Ther Adv Neurol Disord. 2013. PMID: 23277789 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
